SEC Form 4 · accession 0001387131-18-000781
Adamis Pharmaceuticals Corp · ADMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Karen K. Daniels
Officer — VP of Operations
Period of report
Feb 21, 2018
Accepted (ET)
Feb 23, 2018 · 5:57 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000887247
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $2.83 | Feb 21, 2018 | A | 83,467 | A | — | Feb 21, 2028 | Common Stock | 83,467 | 83,467 | D |
| Restricted Stock UnitsF2 | — | Feb 21, 2018 | A | 41,733 | A | — | — | Common Stock | 41,733 | 41,733 | D |
Explanation of responses
- F1The option vests and becomes exercisable as to 1/36 of the option shares on each monthly anniversary of the grant date.
- F2Each restricted stock unit (RSU) represents a contingent right to receive one share of the issuer's common stock. 1/3 of the RSUs vest on each anniversary of the grant date over a three year period provided that the Reporting Person has continued to provide services to the Company during such period.